Dyne Therapeutics (DYN) Submits IND to FDA for DMD Candidate

Published on December 3, 2021

Dyne Therapeutics (DYN) files an investigational new drug application in the United States for a clinical study on its investigational candidate DYNE-251 to address Duchenne Muscular Dystrophy.

Continue reading on website
Other news

Novavax (NVAX) Starts Developing Omicron-Specific COVID Jab

December 3, 2021
Novavax (NVAX) begins evaluating its COVID-19 vaccine against the Omicron variant. The company also starts developing an Omicron-specific COVID-19 vaccine.

Zumiez (ZUMZ) Q3 Earnings Beat Estimates, Sales Increase Y/Y

December 3, 2021
Zumiez's (ZUMZ) third-quarter fiscal 2021 results reflect gains from robust strategic efforts.